A study on efficacy and safety of insulin degludec/insulin aspart in patients with type 2 diabetes
Not Applicable
Active, not recruiting
- Conditions
- Endocrine, nutritional and metabolic diseases
- Registration Number
- KCT0004597
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
inclusion:
1. patients in the outpatient clinic of SNUH, with type 2 diabetes
2. age > 19 years
3. under treatment with once-daily basal insulin (< 1 IU/kg) for more than 4 months
4. HbA1c >= 7% and <=10%
5. marked postprandial hyperglycemia estimated by FPG and HbA1c
6. No change in blood sugar lowering medication taken during the study period
Exclusion Criteria
exclusion:
1. Type 1 diabetes
2. When using insulin other than Insulin glargine U100, Insulin glargine U300, and insulin degludec
3. pregnancy, breast feeding
4. major CVD events or malignancy with the past 6 months
5. uncontrolled hypertension
6. any medications or serious diseases known to significantly affect weight or glucose metabolism
7. irregular diet
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c difference between the 2 insulins
- Secondary Outcome Measures
Name Time Method hypoglycemic events